Study of the Safety, Tolerability and Pharmacokinetics of LY2623091 after Single Oral Dosing in Healthy Subjects
Completed
- Conditions
- chronic kidney diseaseKidney failure10038430
- Registration Number
- NL-OMON34283
- Lead Sponsor
- Chorus LRL (Division of Eli Lilly)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 18
Inclusion Criteria
- Healthy men and women ((postmenopausal/sterilized)
- 18 - 65 years of age, inclusive;
- BMI < 32.5 kg/m2;
- Non smoking or smoking lesss than 10 cigarettes/day
Exclusion Criteria
Suffering from: hepatitis B, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1.5 liters of blood in the 10 months prior the start of this study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method